Supercharge Your Innovation With Domain-Expert AI Agents!

Methods for Diagnosing and Treating Subjects for Pulmonary Exacerbation

a pulmonary exacerbation and pulmonary exacerbation technology, applied in the field of diagnosis and treatment of acute pulmonary exacerbation, can solve the problems of increasing the risk of subsequent decline, increasing the frequency of pulmonary exacerbation, and being difficult to diagnose and defin

Inactive Publication Date: 2020-04-16
NAT JEWISH HEALTH
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This approach provides a sensitive and specific method for diagnosing CF pulmonary exacerbations, enabling effective treatment and reducing the risk of subsequent lung function decline by identifying elevated CD64 expression levels, which correlates with infection and inflammation.

Problems solved by technology

As the disease progresses, patients experience increasingly frequent pulmonary exacerbations, which in turn increases the risk for subsequent decline (Sanders D B, Hoffman L R, Emerson J, et al.
These episodes, which indicate either acquisition of new bacterial infection or a change in the density of previously colonizing bacteria, are poorly defined and difficult to diagnose in the setting of chronic inflammation.
Currently, there is no biochemical test to diagnose CF pulmonary exacerbations and no consensus diagnostic criteria for what constitutes an exacerbation.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for Diagnosing and Treating Subjects for Pulmonary Exacerbation
  • Methods for Diagnosing and Treating Subjects for Pulmonary Exacerbation
  • Methods for Diagnosing and Treating Subjects for Pulmonary Exacerbation

Examples

Experimental program
Comparison scheme
Effect test

example

[0038]Methods: Under IRB approval, blood samples from CF patients (APE) and healthy controls were stained with CD64, CD14 and CD163. CD64 expression on neutrophils was quantitated utilizing Quantum MESF beads.

[0039]Materials:

[0040]FACSCanto II from BD Biosciences

[0041]Quantum MESF FITC bead set from Bangs Laboratories, Inc

[0042]CD14 APC and CD64 FITC from Affymetrix eBiosciences

[0043]Cytochex Vacutainer tubes from Streck, Inc

[0044]Instrumentation: The FACSCanto II linearity was assessed and the FITC PMT was found to be linear down to a channel number of 85 with a R2 of 0.9998.

[0045]Fluorochrome and Marker Selection: CD163 and CD14 were compared for exclusion of monocytes. The stability of CD14 in the presence of heparin made it the marker of choice. PE and FITC-labeled CD64 were analyzed and found to be comparable. FITC was chosen as the more cost-effective reagent.

[0046]Anticoagulant: Heparin, EDTA, Citrate and Cytochex preservative were compared and found to be comparable in marke...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention is related to novel methods for diagnosing and treating acute pulmonary exacerbation in subjects in need thereof.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. patent application Ser. No. 15 / 282,827, filed Sep. 30, 2016, which claims the benefit of priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application Ser. No. 62 / 239,534, filed Oct. 9, 2015, both of which are incorporated herein by reference.FIELD OF THE INVENTION[0002]The field of the present invention involves diagnosing and treating acute pulmonary exacerbation in a subject in need thereof.BACKGROUND[0003]Cystic fibrosis (CF) impacts 30,000 individuals in the United States and 70,000 individuals worldwide (Patient registry: Annual Data Report. Cystic Fibrosis Foundation 2012; Bethesda, Md.). Mortality from the disease primarily occurs due to progressive respiratory infection and an excessive inflammatory response in the CF lung (Davis P B, Drumm M, Konstan M W. Cystic fibrosis. Am J Respir Crit Care Med 1996; 154:1229-56; Chmiel J F, Berger M, Konstan M W. The role of inflammation ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): G01N33/68C12Q1/6883G01N33/569G01N33/49
CPCG01N33/56972C12Q1/6883C12Q2600/158G01N33/6893G01N2333/70535G01N2333/70596G01N2800/382G01N33/4915
Inventor SAAVEDRA, MILENEKNIGHT, VIJAYA
Owner NAT JEWISH HEALTH
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com